These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 38786075)

  • 21. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents.
    Su B; Zhu X; Jiang Y; Wang L; Zhao N; Ran X; Zheng X; Guo H
    Leuk Lymphoma; 2019 Jun; 60(6):1381-1388. PubMed ID: 30516074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
    Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
    Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
    Mai EK; Benner A; Bertsch U; Brossart P; Hänel A; Kunzmann V; Naumann R; Neben K; Egerer G; Ho AD; Hillengass J; Raab MS; Neubauer A; Peyn A; Ko YD; Peter N; Scheid C; Goldschmidt H
    Br J Haematol; 2016 Jun; 173(5):731-41. PubMed ID: 26990892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
    Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)].
    ; ;
    Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):341-346. PubMed ID: 32370461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [High dose melphalan (HDM) is superior to cyclophosphamide plus etoposide and busulfan (CVB) as the conditioning regimen in autologous stem cell transplantation for multiple myeloma].
    Gu JL; Li J; Liu JR; Zou WY; Huang BH; Zheng D; Wang HH
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):732-737. PubMed ID: 31648473
    [No Abstract]   [Full Text] [Related]  

  • 27. [Impact of autologous hematopoietic stem cell transplantation on the efficacy of CAR-T treatment of relapsed/refractory multiple myeloma].
    Ding MJ; Jie XX; Li HJ; Xu ZY; Nian L; Qi KM; Yan ZL; Zhu F; Cao J; Zhang HX; Xu KL; Cheng H; Li ZY
    Zhonghua Nei Ke Za Zhi; 2024 Jun; 63(6):587-592. PubMed ID: 38825927
    [No Abstract]   [Full Text] [Related]  

  • 28. Therapeutic progress in relapsed/refractory multiple myeloma.
    Chen Q; Zhang M; Zheng S; Tong Y; Tan Y
    Ann Hematol; 2024 Jun; 103(6):1833-1841. PubMed ID: 38609727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
    Minnie SA; Hill GR
    Front Immunol; 2021; 12():651288. PubMed ID: 33777050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!
    Kazandjian D; Dew A; Hill E
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101150. PubMed ID: 32139015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival Analysis of Newly Diagnosed Multiple Myeloma Patients after Frontline Autologous Stem Cell Transplantation in a Real-Life Setting.
    Garrido D; Bove V; Villano F; Riva E
    Acta Medica (Hradec Kralove); 2023; 66(3):117-121. PubMed ID: 38511422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time.
    Kazandjian D; Landgren O
    Clin Adv Hematol Oncol; 2019 Oct; 17(10):559-568. PubMed ID: 31730582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma.
    Hagen PA; Stiff P
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):e98-e107. PubMed ID: 30537552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
    Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
    Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal antibodies as an addition to current myeloma therapy strategies.
    Jullien M; Touzeau C; Moreau P
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.
    Gay F; Engelhardt M; Terpos E; Wäsch R; Giaccone L; Auner HW; Caers J; Gramatzki M; van de Donk N; Oliva S; Zamagni E; Garderet L; Straka C; Hajek R; Ludwig H; Einsele H; Dimopoulos M; Boccadoro M; Kröger N; Cavo M; Goldschmidt H; Bruno B; Sonneveld P
    Haematologica; 2018 Feb; 103(2):197-211. PubMed ID: 29217780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes.
    Kesireddy M; Holstein SA
    Expert Rev Clin Pharmacol; 2022 Jan; 15(1):19-31. PubMed ID: 35061547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
    Voorhees PM; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Murphy S; Lutska Y; Pei H; Ukropec J; Vermeulen J; de Boer C; Hoehn D; Lin TS; Richardson PG
    Blood; 2020 Aug; 136(8):936-945. PubMed ID: 32325490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy of multiple myeloma.
    Minnie SA; Hill GR
    J Clin Invest; 2020 Apr; 130(4):1565-1575. PubMed ID: 32149732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.